Lp(a): The genetic cardiovascular marker you need to know about

You’ve checked your cholesterol, your ApoB is fine, your blood pressure is normal. And yet someone in your family had an “unexplained” heart attack before age 60.

The answer may lie in a test that most adults still have never had: lipoprotein(a), abbreviated Lp(a). It is one of the most important and most underestimated inherited cardiovascular risk factors in modern medicine. Roughly 1 in 5 people worldwide have elevated levels — yet most will never know.

Unlike LDL cholesterol, which you can lower with diet and statins, Lp(a) is determined mostly by your genes. You can’t meaningfully change it through nutrition. You can’t eliminate it at the gym. But you can — and should — know about it.

What you’ll learn:

• What Lp(a) is and why it’s different from cholesterol
• How your genes determine Lp(a) levels
• Optimal values and how to interpret the test
• Why Lp(a) is a triple threat to your arteries
• Lp(a) vs ApoB vs LDL: which matters most?
• Strategies to reduce risk even with high Lp(a)
• Upcoming therapies in 2026
• How to monitor your cardiovascular risk with SuperAge
• Frequently asked questions

---

What is lipoprotein(a)?

Quick definition: Lipoprotein(a), or Lp(a), is a particle similar to LDL with an additional protein called apolipoprotein(a) that makes it particularly harmful to arteries and resistant to conventional treatments.

To understand Lp(a), picture an LDL cholesterol particle — the kind that transports fat through your blood. Now add a molecular “hook”: apolipoprotein(a), a protein that binds to apoB-100 on the LDL particle’s surface via a disulfide bridge.

That hook changes everything. Lp(a) isn’t simply “more cholesterol.” It’s a particle with unique properties:

• Atherogenic: it infiltrates arterial walls like LDL, but stays there longer
• Pro-thrombotic in plaque biology: apo(a) structurally resembles plasminogen — a molecule involved in clot breakdown — and may interfere with fibrin handling in damaged arteries
• Pro-inflammatory: it carries oxidized phospholipids that trigger chronic inflammation

In other words, Lp(a) is a triple threat to your cardiovascular system.

A brief history of the discovery

Lp(a) was identified in 1963 by Norwegian geneticist Kare Berg. For decades it remained a biochemical curiosity, ignored in clinical practice. Only in recent years, thanks to large-scale genetic studies and clinical trials with novel therapies, has it become one of the hottest topics in cardiology worldwide. Experts dubbed 2024 “the year of lipoprotein(a).”

---

Your genes decide (almost) everything

Here’s what makes Lp(a) unique among cardiovascular biomarkers: levels are predominantly genetically determined. The European Atherosclerosis Society describes Lp(a) concentration as more than 90% determined by genetic variability at the LPA locus.

The responsible gene is LPA, located on chromosome 6. Variation between individuals depends primarily on the number of kringle IV type 2 repeats in the gene. Lp(a) testing reveals a single genetic risk, but polygenic risk scores aggregate thousands of variants — including LPA variants — into a comprehensive cardiovascular risk picture:

• Fewer repeats → smaller apo(a) protein → higher Lp(a) levels → greater risk
• More repeats → larger apo(a) protein → lower Lp(a) levels → lower risk

This means:

1. Lp(a) is stable throughout your lifetime: unlike LDL cholesterol, it doesn’t fluctuate significantly with diet, exercise, or traditional medications
2. It’s inherited in an autosomal dominant pattern: if one parent has high Lp(a), each child has a 50% chance of inheriting it
3. A single test is enough: since levels are stable, in most cases you only need to measure it once in your life

Ethnic variability

Lp(a) levels vary significantly across populations:

Population	Median Lp(a) levels	Notes
African descent	Highest	Up to 2–3 times the European median
South Asian	Medium-high	Higher prevalence of elevated levels
European/Caucasian	Medium	Skewed distribution
East Asian	Lowest	Lower median levels

These differences have important implications for personalizing risk thresholds and interpreting results.

---

Optimal values: how to read your test

Lp(a) can be measured in two different units, and it’s crucial not to confuse them:

Risk level	mg/dL	nmol/L	Interpretation
Lower-risk range	< 30	< 75	Lp(a)-related risk is less likely
Grey zone	30–50	75–125	Interpret with family history and total ASCVD risk
High	≥ 50	≥ 125	Risk-enhancing level; intensify prevention
Very high	Often ≥ 100	≥ 250	Substantially higher lifetime ASCVD risk

Current guidelines use thresholds rather than perfect conversions. The 2026 ACC/AHA multisociety dyslipidemia guideline treats ≥50 mg/dL or ≥125 nmol/L as high and notes that 250 nmol/L is associated with at least a two-fold higher long-term risk of heart attack or stroke.

Watch out for units of measurement

A common mistake is confusing mg/dL with nmol/L. The conversion isn’t linear because it depends on the size of apo(a) — which varies from person to person. That’s why the European Atherosclerosis Society (EAS) guidelines recommend measuring in nmol/L, which is more accurate because it counts particles rather than weighing mass.

Practical tip: when you get your lab results, always check which unit of measurement was used. A value of “50” in mg/dL and “50” in nmol/L have very different meanings.

Who should get tested

The 2026 ACC/AHA multisociety dyslipidemia guideline, the National Lipid Association, and the European Atherosclerosis Society now support measuring Lp(a) at least once in adulthood. It’s especially important if:

• You have a family history of heart attack, stroke, or premature cardiovascular disease (before age 55 in men, 65 in women)
• You have high LDL cholesterol despite a healthy lifestyle
• You’ve had a cardiovascular event without traditional risk factors
• You have aortic stenosis (narrowing of the aortic valve)
• You want a comprehensive assessment of your cardiovascular risk profile

For broader lab planning, pair Lp(a) with the markers in a complete longevity blood test panel. For a detailed breakdown of how to order the test, interpret your results by unit (mg/dL vs nmol/L), and understand what to do if your levels are elevated, see our complete Lp(a) testing guide.

---

The triple threat of Lp(a)

Lp(a) damages the cardiovascular system through three distinct and synergistic mechanisms.

1. Accelerated atherogenesis

Like LDL, Lp(a) crosses the arterial wall and deposits cholesterol. But it does so more efficiently because apo(a) slows its clearance. The result is faster buildup of atherosclerotic plaques, especially in the coronary arteries and aorta.

Large-scale studies show that risk rises continuously as Lp(a) rises. In the 2026 ACC/AHA guideline summary, ≥50 mg/dL or ≥125 nmol/L is associated with about a 1.4-fold higher long-term risk of heart attack or stroke, while 250 nmol/L is associated with at least a two-fold higher risk.

2. Thrombogenicity

Apolipoprotein(a) has a three-dimensional structure that resembles plasminogen, the key molecule in the fibrinolytic system (the one that helps dissolve blood clots). In damaged, plaque-rich arteries, Lp(a) may interfere with fibrin handling and local clot resolution.

In practical terms: if a small clot forms in an artery already narrowed by plaque, Lp(a) may make the local environment more dangerous. This does not mean Lp(a) is a general predictor of venous clots; the strongest clinical evidence is for atherosclerotic events and aortic valve stenosis.

3. Chronic inflammation

Lp(a) carries oxidized phospholipids (OxPL), highly inflammatory molecules. These phospholipids activate immune cells in the arterial walls, fueling a cycle of chronic inflammation that:

• Destabilizes existing plaques (making them more prone to rupture)
• Promotes vascular remodeling
• Contributes to calcific aortic stenosis, a condition where the aortic valve progressively hardens

The link to aortic stenosis

This is a relatively recent but critical discovery: elevated Lp(a) levels are a causal risk factor for aortic stenosis, the most common valvular disease in older adults. Apo(a) and oxidized phospholipids promote valve calcification, accelerating a process that leads to heart failure if left untreated.

---

Lp(a) vs ApoB vs LDL cholesterol: which matters most?

If you follow SuperAge, you already know the importance of ApoB. Here’s how Lp(a) fits into the picture:

Parameter	What it measures	Modifiable with lifestyle?	Modifiable with medication?
LDL cholesterol	Mass of cholesterol in LDL particles	Yes (moderately)	Yes (statins, ezetimibe)
ApoB	Total number of atherogenic particles	Yes (moderately)	Yes (statins, PCSK9i)
Lp(a)	Specific subtype of LDL particle with apo(a)	No	In development (2026)

The key point: these three markers are not interchangeable but complementary.

• ApoB tells you the total number of dangerous particles you have — it’s the best overall predictor. For a practical guide to interpreting your number, see ApoB normal range by age and risk category
• LDL is the most widely used test but the least precise of the three
• Lp(a) tells you whether you carry an additional genetic risk that LDL and ApoB alone don’t capture

A practical example: you can have perfect ApoB (< 80 mg/dL) and normal LDL, but if your Lp(a) is > 50 mg/dL, you still face elevated cardiovascular risk that none of the other tests would reveal.

For a comprehensive assessment, you need all three.

---

7 strategies to reduce risk even with high Lp(a)

You can’t change your genes. But you can dramatically reduce the impact of high Lp(a) by aggressively managing every other modifiable risk factor.

1. Lower your ApoB as much as possible

Why it works: if you have high Lp(a), every other atherogenic particle in your blood amplifies the damage. Reducing ApoB (and therefore LDL) to the lowest possible level decreases the total “burden” on your arteries.

How to do it:

• Discuss an aggressive ApoB target with your doctor (< 65 mg/dL, or < 55 mg/dL if high-risk)
• Statins reduce ApoB by 30–50%
• Adding ezetimibe provides an additional 15–20%
• PCSK9 inhibitors can reduce ApoB by up to 60%

Important: statins do NOT lower Lp(a) — in fact, some studies suggest a slight increase of 10–20%. This is not a reason to avoid them: the net benefit in cardiovascular risk reduction remains strongly positive.

2. Control inflammation

Why it works: Lp(a) is pro-inflammatory. Reducing baseline inflammation mitigates one of its three damage mechanisms.

How to do it:

• Monitor high-sensitivity CRP (hs-CRP): target < 1 mg/L
• Adopt a diet rich in omega-3 from food sources (fatty fish, flaxseed, walnuts)
• Cut back on ultra-processed foods, a major driver of chronic inflammation
• Maintain a healthy weight: visceral fat produces inflammatory cytokines

3. Optimize your blood pressure

Why it works: high blood pressure damages the endothelium (the inner lining of your arteries), creating more entry points for Lp(a).

How to do it:

• Target: < 120/80 mmHg for maximum protection
• Limit sodium to < 2,300 mg/day (ideally < 1,500 mg)
• Increase potassium through fruits and vegetables
• Get 150 minutes/week of moderate aerobic activity

4. Manage your blood sugar

Why it works: chronic hyperglycemia accelerates glycation of particles, including Lp(a), making them more atherogenic.

How to do it:

• Keep HbA1c < 5.7% (prediabetes threshold)
• Monitor fasting blood glucose: target < 100 mg/dL (5.6 mmol/L)
• If you use a continuous glucose monitor (CGM), aim for low glycemic variability
• Post-meal exercise reduces blood sugar spikes

5. Move every day (even though it won’t change Lp(a))

Why it works: exercise doesn’t directly lower Lp(a), but it improves virtually every other cardiovascular factor — blood pressure, insulin sensitivity, endothelial function, lipid profile.

How to do it:

• Aerobic: 150–300 minutes/week at moderate intensity or 75–150 minutes at high intensity
• Resistance training: 2–3 sessions/week to maintain muscle mass and metabolism
• VO2 max goal: improving cardiorespiratory fitness is the single most protective factor against cardiovascular mortality

Expected results: after 8–12 weeks of consistent training, expect measurable improvements in blood pressure, HRV, resting heart rate, and VO2 max.

6. Be cautious with niacin

Why it matters: niacin (vitamin B3) at pharmacological doses can reduce Lp(a) by roughly 20–30% in some people, but lowering the number has not translated into clear cardiovascular outcome benefit in modern trials.

What to know:

• Effective doses (1,000–2,000 mg/day) are much higher than nutritional amounts
• Effectiveness varies and does not solve the underlying inherited risk
• Side effects include skin flushing, gastrointestinal issues, and potential hepatotoxicity
• Current guidelines do not recommend niacin as a routine Lp(a)-lowering strategy
• This is not a DIY decision: only consider it if a physician has a specific reason and monitors safety labs

7. Quit smoking (if you smoke)

Why it works: smoking multiplies cardiovascular risk synergistically with Lp(a). It damages the endothelium, increases inflammation, and promotes thrombosis — the very same three mechanisms as Lp(a).

The impact: quitting smoking cuts cardiovascular risk by 50% within one year. With high Lp(a), eliminating smoking is arguably the single intervention with the highest cost-benefit ratio.

---

Upcoming therapies: 2026 could change everything

For the first time in history, there are drugs in phase 3 clinical trials that specifically lower Lp(a). Here are the most promising:

Drug	Mechanism	Lp(a) reduction	Trial phase	Expected results
Pelacarsen	Antisense oligonucleotide	35–80%	Phase 3 (Lp(a)HORIZON, n=8,323)	Primary completion estimated June 2026
Olpasiran	siRNA	Up to 95%+ in phase 2	Phase 3 (OCEAN(a)-Outcomes, n=7,297)	Estimated completion March 2028
Lepodisiran	siRNA (long-interval dosing)	93.9% (ALPACA)	Phase 3 (ACCLAIM-Lp(a), planned n≈17,300)	Estimated completion March 2029
Zerlasiran	siRNA	>80% in phase 2	Phase 2 data published	Outcomes data still pending
Muvalaplin	Small oral molecule	Up to 85.8% in phase 2	Phase 3 recruiting (MOVE-Lp(a), planned n≈10,450)	Estimated completion March 2031

How they work

The most advanced drugs act at the genetic level:

• Pelacarsen is an antisense oligonucleotide that binds to the messenger RNA of apo(a) in the liver, preventing its production. It’s administered as a subcutaneous injection once a month.
• Olpasiran is an siRNA (small interfering RNA) that degrades apo(a) messenger RNA before it’s translated into protein. It showed reductions exceeding 95% in phase 2, with a single injection every 12 weeks.
• Lepodisiran is another siRNA that achieved a 93.9% Lp(a) reduction in the phase 2 ALPACA trial, with the potential for long-interval dosing — a major convenience advantage.
• Muvalaplin is the only oral option in development: it blocks Lp(a) assembly by preventing the binding of apo(a) to apoB-100.

The Lp(a)HORIZON trial for pelacarsen enrolled 8,323 patients with established ASCVD and Lp(a) ≥ 70 mg/dL. As of June 26, 2026, ClinicalTrials.gov lists it as active, not recruiting, with primary completion estimated for June 30, 2026. It is the first large outcomes trial to evaluate whether lowering Lp(a) actually translates into fewer heart attacks and strokes — not just better numbers on a blood test.

Important note: as of June 2026, no drug has been approved by the FDA specifically to lower Lp(a). Approval will require evidence that these therapies reduce cardiovascular events, which these ongoing phase 3 trials are designed to evaluate.

---

How SuperAge helps you monitor cardiovascular risk

Knowing your Lp(a) is the first step. But true protection comes from continuously monitoring all the risk factors you can control.

Biological age tracking

SuperAge calculates your biological age by integrating data from Apple Watch and your blood test results. If you have high Lp(a), the factors you can control — resting heart rate, HRV, VO2 max, physical activity — become even more important.

All your biomarkers in one place

Enter your blood test results — including ApoB, LDL, CRP, HbA1c — and visualize trends over time. Seeing the full picture lets you know whether your strategies are working.

Personalized insights

SuperAge doesn’t just show you numbers: it helps you interpret them in the context of your biological age and overall risk profile.

---

Frequently asked questions

Does high Lp(a) mean I’ll definitely have a heart attack?

No. Elevated Lp(a) levels increase your statistical risk, but they’re not a death sentence. Many people with high Lp(a) live long lives free of cardiovascular events, especially when they actively manage all other risk factors. The key is aggressive prevention of modifiable risk factors.

Do I need to repeat the Lp(a) test every year?

In most cases, no. Because levels are genetically determined and stable over time, a single test is generally sufficient, and the 2026 ACC/AHA guideline notes that repeat testing is generally not needed. Exceptions include pregnancy, menopause, chronic kidney disease, major inflammatory illness, or therapies that may affect levels.

Can statins make Lp(a) worse?

Some studies show a slight increase (10–20%) in Lp(a) with statins. However, the overall benefit of statins in reducing cardiovascular risk far outweighs this effect. It’s not a reason to stop therapy — discuss it with your doctor.

Can diet and exercise lower Lp(a)?

Unfortunately, no — not in any meaningful way. Lp(a) is resistant to lifestyle interventions. However, diet and exercise improve every other cardiovascular risk factor, making high Lp(a) less dangerous overall.

What’s the difference between Lp(a) and LDL?

LDL (low-density lipoprotein) is a family of particles that carry cholesterol through the blood. Lp(a) is a specific subtype of LDL with the addition of apolipoprotein(a), which makes it more atherogenic, more thrombogenic, and resistant to conventional medications.

---

Key takeaways

• Lp(a) is the most underestimated inherited cardiovascular risk factor: it affects 1 in 5 people worldwide, yet is rarely tested
• Levels are mostly determined by genetics: a single test is sufficient for life in most cases
• It’s a triple threat: it promotes atherosclerosis, thrombosis, and inflammation through unique mechanisms
• You can’t change it with diet and exercise: but you can dramatically reduce overall risk by managing all other modifiable factors
• Powerful targeted therapies are in outcomes trials, but event-reduction proof and FDA approval are still pending
• The test is affordable and only needs to be done once: ask your doctor for an Lp(a) measurement at your next blood draw

---

Start protecting your heart today

Lipoprotein(a) is one of the few cardiovascular risk factors you can’t directly modify. But you can know about it, monitor it, and build a protection strategy around it.

The first step? Ask your doctor to add Lp(a) to your next lipid panel. The second? Start tracking all the factors you can control.

Ready to take charge of your cardiovascular health? Download SuperAge and start monitoring your biological age, biomarkers, and cardiovascular fitness — all in one app.

---

References

1. ACC/AHA/Multisociety — “2026 Guideline on the Management of Dyslipidemia” — Circulation/JACC (2026).
2. American Heart Association — Scientific Statement on Lipoprotein(a) as a causal risk factor for ASCVD (2022).
3. European Atherosclerosis Society (EAS) — Consensus Statement on Lp(a) (2022).
4. National Lipid Association — Focused update on use of Lp(a) in clinical practice (2024).
5. Shah NP et al. — “Lipoprotein(a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems” — Journal of the American Heart Association (2024).
6. O’Donoghue ML et al. — Lp(a)HORIZON trial: pelacarsen for cardiovascular risk reduction — ClinicalTrials.gov NCT04023552.
7. Nissen SE et al. — “Olpasiran phase 2 results (OCEAN(a)-DOSE)” — New England Journal of Medicine (2023).
8. Koren MJ et al. — “Oral Muvalaplin for Lowering of Lipoprotein(a)” — JAMA (2024).
9. Nissen SE et al. — “Lepodisiran for Lipoprotein(a) Lowering: phase 2 ALPACA trial results” — JAMA (2025).
10. Nissen SE et al. — “Zerlasiran: A Small-Interfering RNA Targeting Lipoprotein(a)” — JAMA (2024).

---

Last updated: 2026-06-26. This article is reviewed regularly to ensure accuracy.

The information provided does not replace professional medical advice. Consult your physician before making changes to your therapy or testing regimen.